← Leaderboards
Gustavo Adolfo Heresi Davila
Cleveland Clinic Lerner Com-Cwru
$2,141,417
Attributed
$2,141,417
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $873.9K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,141,417 · 3
By mechanism
UH3$873,890 · 1
K23$834,404 · 1
UG3$433,123 · 1
Top collaborators
No co-investigators on record.
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Luca Cucullo$4,690,569
- Micheala A Aldred$9,408,014
- Serpil C. Erzurum$45,061,611
- Seth Bauer$708,473
- W Hwilson Tang$17,252
Others in their field
Top investigators on “Targeted Treatment”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$330,005,266
- Judith S. Currier · University Of California Los Angeles$272,870,456
- Peter C Adamson · National Childhood Cancer Foundation$268,343,924
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$172,705,574
Research focus
Targeted TreatmentSurvival RateInsulin ResistancePlasmaPulmonary Vascular ResistanceRight Ventricular FunctionGlucoseHigh Density Lipoprotein CholesterolMetabolicPhenotypeProductionPulmonary Arterial HypertensionRandomizedReportingDiet And ExerciseDietary InterventionHeartHeart FailureLipidsLungMetabolismCessation Of LifePrematureVasodilator Agents
Grant awards (7)
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension$873,890
UH3 · FY2025 · HL · contact PI
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension$433,123
UG3 · FY2024 · HL · contact PI
Insulin Resistance in Pulmonary Arterial Hypertension$149,888
K23 · FY2019 · HL · contact PI
Insulin Resistance in Pulmonary Arterial Hypertension$165,683
K23 · FY2018 · HL · contact PI
Insulin Resistance in Pulmonary Arterial Hypertension$184,601
K23 · FY2017 · HL · contact PI
Insulin Resistance in Pulmonary Arterial Hypertension$184,859
K23 · FY2016 · HL · contact PI
Insulin Resistance in Pulmonary Arterial Hypertension$149,373
K23 · FY2015 · HL · contact PI